Adsorption of oxacalcitriol by polysulphone haemodialyser in patients with secondary hyperparathyroidism

British Journal of Clinical Pharmacology

Volumn 58, Issue 5, 2004, Pages 488-495

  Tsuruoka, Shuichi ^a   Yamamoto, Hisashi ^a   Ioka, Takashi ^a   Ando, Hitoshi ^a   Saito, Tetsuo ^b   Fujimura, Akio ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Moka Hospital   (Japan)

Author keywords

Adsorption; Haemodialyser; Oxacalcitriol; Polysulphone; Secondary hyperparathyroidism

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; CALCIUM CARBONATE; CALCIUM ION; PARATHYROID HORMONE; PHOSPHATE; PHOSPHATE BINDING AGENT; POLYSULFONE; RECOMBINANT ERYTHROPOIETIN;

ADSORPTION; ADULT; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG INFUSION; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PARATHYROID HORMONE BLOOD LEVEL; PHARMACODYNAMICS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SECONDARY HYPERPARATHYROIDISM;

ADSORPTION; CALCITRIOL; CLINICAL PROTOCOLS; FEMALE; HUMANS; HYPERPARATHYROIDISM, SECONDARY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PARATHYROID HORMONE; POLYMERS; RENAL DIALYSIS; SULFONES;

EID: 9144233546     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02204.x     Document Type: Article

References (20)

1. Llasch F, Bover J. Renal osteodystrophies. In Brenner and Rector's the Kidney, ed Brenner BB. Philadelphia: W.B. Saunders, 1996; 2187-273.
2. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy- cholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-43.
3. Brown AJ, Ritter CR, Finch JL et al. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion. J Clin Invest 1989; 84: 728-32.
4. Finch JL, Brown AJ, Mori T et al. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH) 2D3. J Bone Miner Res 1992; 7: 835-9.
5. Hirata M, Endo K, Katsumata K et al. A comparison between 1,25-dihydroxy-22-oxavitamin D(3) and 1,25-dihydroxyvitamin D(3) regarding suppression of parathyroid hormone secretion and calcaemic action, Nephrol Dial Transplant 2002; 17 (Suppl. 10): 41-5.
6. Tsukamoto Y, Hanaoka M, Matsuo T et al. Effect of 22-oxacalcitriol on bone histology of hemodialyzed patients with severe secondary hyperparathyroidism. Am J Kidney Dis 2000; 35: 458-64.
7. Gabutti L, Taminelli-Betraminelli L, Marone C. Clearance of ceftriaxone during hemodialysis using cuprophane, hemophane and polysulfone dialyzers. Eur J Clin Pharmacol 1997; 53: 123-6.
8. Gehr T, Sica D, Slugg P et al. The pharmacokinetics of pravastatin in patients on chronic hemodialysis. Eur J Clin Pharmacol 1997; 53: 117-21.
9. Tsuruoka S, Sugimoto KI, Hayasaka T et al. Ranitidine clearance during hemodialysis with high-flux membrane: comparison of polysulfone and cellulose acetate hemodialyzers. Eur J Clin Pharmacol 2000; 56: 581-3.
10. Tsuruoka S, Osono E, Nishiki K et al. Removal of digoxin by column for specific adsorption of beta(2)-microglobulin: a potential use for digoxin intoxication. Clin Pharmacol Ther 2001; 69: 422-30.
11. Ishigai M, Asoh Y, Kumaki K. Determination of 22-oxacalcitriol, a new analog of 1 alpha,25-dihydroxyvitamin D3, in human serum by liquid chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl 1998; 706: 261-7.
12. Frolich M, Walma ST, Paulson C et al. Immunoradiometric assay for intact human parathyroid hormone: characteristics, clinical application and comparison with a radio-immunoassay. Ann Clin Biochem 1990; 27: 69-72.
13. Tsuruoka S, Sugimoto K, Ohmori M et al. Chronotherapy of high-dose 1,25-dihydroxyvitamin D3 in hemodialysis patients with secondary hyperparathyroidism: a single-dose study. Clin Pharmacol Ther 1999; 66: 609-16.
14. Mori H, Hiraoka K, Yorifuji R et al. Adsorption of human recombinant erythropoietin on dialysis membrane in vitro. Artif Organs 1994; 18: 725-8.
15. Kobayashi T, Tsugawa N, Okano T et al. The binding properties, with blood proteins, and tissue distribution of 22-oxa-1 alpha,25-dihydroxyvitamin D3, a noncalcemic analogue of 1 alpha, 25-dihydroxyvitamin D3, in rats. J Biochem (Tokyo) 1994; 115: 373-80.
16. Nakagawa K, Imagaki O, Iwaki R et al. Study of the binding capacity of FUT-175 on dialysis membrane. Jpn J Artif Organs 1991; 20: 27-31.
17. Moachon N, Boullange C, Fraud S et al. Influence of the charge of low molecular weight proteins on their efficacy of filtration and/or adsorption on dialysis membranes with different intrinsic properties. Biomaterials 2002; 23: 651-8.
18. Scott MK, Mueller BA, Sowinski KM. The effects of peracetic acid-hydrogen peroxide reprocessing on dialyzer solute and water permeability. Pharmacotherapy 1999; 19: 1042-9.
19. Amerling A, Cu C, Dubrow A et al. Complications during hemodialysis. In Clinical Dialysis, eds Nissenson AR, Fine RN, Gentile DE. London: Prentice Hall International Inc., 1995; 233-67.
20. Opatrny K Jr, Krouzecky A, Wirth J et al. The effects of a polyacrylonitrile membrane and a membrane made of regenerated cellulose on the plasma concentrations of erythropoietin during hemodialysis. Artif Organs 1998; 22: 816-20.